Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 295, Issue 4, 2008, Pages

  Lovren, Fina ^a,b,c   Pan, Yi ^a,b,c   Quan, Adrian ^a,b,c   Teoh, Hwee ^a,b,c   Wang, Guilin ^a,b,c   Shukla, Praphulla C ^a,b,c   Levitt, Kevin S ^a,b,c   Oudit, Gavin Y ^c   Al Omran, Mohammed ^b,f   Stewart, Duncan J ^a,b,c,e   Slutsky, Arthur S ^b,c,e   Peterson, Mark D ^a,b,c   Backx, Peter H ^c,d,e   Penninger, Josef M ^f   Verma, Subodh ^a,b,c,e,g  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f KING KHALID UNIVERSITY HOSPITAL   (Saudi Arabia)

^g ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Angiogenesis; Atherogenesis; Endothelium

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; APOLIPOPROTEIN E; REACTIVE OXYGEN METABOLITE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; ATTENUATION; BLOOD VESSEL REACTIVITY; CELL ADHESION; CELL MATURATION; CELL MIGRATION; CONTROLLED STUDY; DRUG ACTIVITY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HEART PROTECTION; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MONOCYTE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULARIZATION;

ANGIOTENSIN II; ANIMALS; APOLIPOPROTEINS E; ATHEROSCLEROSIS; CELLS, CULTURED; DIETARY FATS; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GENE THERAPY; HUMANS; MALE; MICE; MICE, KNOCKOUT; NEOVASCULARIZATION, PHYSIOLOGIC; PEPTIDYL-DIPEPTIDASE A; REACTIVE OXYGEN SPECIES; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSDUCTION, GENETIC; VASODILATION;

EID: 57049183645     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00331.2008     Document Type: Article

References (18)

1. Anton L, Merrill DC, Neves LA, Brosnihan KB. Angiotensin-(1-7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT(1-7) receptor. Endocrine 32: 212-218, 2007.
2. Chappel MC, Ferrario CM. ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7). Kidney Int 70: 8-10, 2006.
3. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveira-dos-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 417: 822-828, 2002.
4. Danilczyk U, Eriksson U, Oudit GY, Penninger JM. Physiological roles of angiotensin-converting enzyme 2. Cell Mol Life Sci 61: 2714-2719, 2004.
5. Danilczyk U, Penninger JM. Angiotensin-converting enzyme II in the heart and the kidney. Circ Res 98: 463-471, 2006.
6. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 87: E1-9, 2000.
7. Dzau V. The cardiovascular continuum and renin-angiotensin- aldosterone system blockade. J Hypertens Suppl 23: S9-17, 2005.
8. Fleming I, Fisslthaler B, Dixit M, Busse R. Role of PECAM-1 in the shear-stress-induced activation of Akt and the endothelial nitric oxide synthase (eNOS) in endothelial cells. J Cell Sci 118: 4103-4111, 2005.
9. Iusuf D, Henning RH, van Gilst WH, Roks AJ. Angiotensin-(1-7): pharmacological properties and pharmacotherapeutic perspectives. Eur J Pharmacol 585: 303-312, 2008.
10. Machado RD, Santos RA, Andrade SP. Mechanisms of angiotensin-(1-7)-induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol 280: R994-R1000, 2001.
11. Oudit GY, Crackower MA, Backx PH, Penninger JM. The role of ACE2 in cardiovascular physiology. Trends Cardiovasc Med 13: 93-101, 2003.
12. Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM, Scholey JW. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 168: 1808-1820, 2006.
13. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29: e45, 2001.
14. Rueckschloss U, Quinn MT, Holtz J, Morawietz H. Dose-dependent regulation of NAD(P)H oxidase expression by angiotensin II in human endothelial cells: protective effect of angiotensin II type 1 receptor blockade in patients with coronary artery disease. Arterioscler Thromb Vasc Biol 22: 1845-1851, 2002.
15. Savoia C, Schiffrin EL. Inhibition of the renin angiotensin system: implications for the endothelium. Curr Diab Rep 6: 274-278, 2006.
16. Tallant EA, Clark MA. Molecular mechanisms of inhibition of vascular growth by angiotensin-(1-7). Hypertension 42: 574-579, 2003.
17. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 108: 2054-2059, 2003.
18. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme homologue ACE2. Circulation 108: 1707-1712, 2003.